Study reveals diabetes drugs could slash your risk of developing brain diseases by up to 31%. Here's what you need to know about this game-changing discovery.
A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...